A major development has emerged in the ongoing investigation into fake, narcotic, and illegal pharmaceutical trade in Agra, as the Enforcement Directorate (ED) has formally entered the case. The agency has sought detailed reports of three criminal cases registered in 2025, marking its first direct involvement in the matter.
Officials confirmed that the ED has requested comprehensive case files related to three separate FIRs lodged in August 2025 at Kotwali and MM Gate police stations. These cases involve allegations of large-scale manufacturing and distribution of counterfeit and controlled drugs across Agra and Lucknow, with suspected financial irregularities running into crores.
Three Cases Involving Counterfeit, Narcotic and Bribed‑STF Angle
One of the cases also includes allegations that an accused attempted to bribe an STF inspector with ₹1 crore, further intensifying the seriousness of the investigation. According to police records, the first case was registered on August 25, 2025, at MM Gate police station against multiple individuals, including Yunus, Warish, Vicky Kumar, Subhash Kumar, Himanshu, and Farhan. During coordinated action by the Food and Drug Administration and the Special Task Force, large quantities of suspected illegal medicines were seized.
FCRF Academy Launches Premier Anti-Money Laundering Certification Program
The second case, registered on August 28, 2025, involves several pharmaceutical firms and individuals, including Himanshu Aggarwal of He Maa Medico, Raja alias A.K. Rana of Meenakshi Pharma, Vicky of Kumar New Baba Pharma (Lucknow), and Subhash Kumar of Parvati Traders (Lucknow). During enforcement action in this case, accused Himanshu Aggarwal allegedly attempted to offer a ₹1 crore bribe to an STF inspector, which was immediately seized and reported. The incident had drawn significant attention across the state and led to additional charges under anti-corruption laws.
The third case was registered at Kotwali police station against Sanjay Bansal, his son Sohit Bansal, and brother Mukesh Bansal, all suspected of involvement in the illegal drug supply chain. Preliminary investigations had earlier indicated the presence of a well-organised syndicate involved in circulating counterfeit medicines worth several crores every month. Authorities believe that the network was also dealing in life-saving drugs, making the operation particularly dangerous for public health.
ED Steps In Under PMLA, Eyes Money‑Laundering Trails
Investigators noted that individuals who were earlier working in small roles in medical shops have allegedly become major wholesalers in the illicit pharmaceutical trade, raising concerns about rapid financial gains through illegal means.
With the ED’s entry, the case is expected to be examined under the Prevention of Money Laundering Act (PMLA). Officials believe that financial trails, benami transactions, and unexplained wealth accumulation may now become central to the probe.
Sources indicated that ED intervention could expose deeper financial linkages and uncover additional individuals connected to the alleged syndicate. The agency is expected to analyze bank records, property transactions, and business networks linked to the accused. The ED headquarters has already communicated with the police commissioner’s office, seeking detailed reports of all three cases. The documents are being compiled under the supervision of senior police officials in the city zone.
Expansion of Probe, Health‑Threat and Laundering Nexus
Officials stated that the investigation may expand significantly once financial irregularities are mapped, potentially revealing a wider interstate or even multi-state pharmaceutical racket.
Experts believe that the case highlights a growing nexus between counterfeit drug manufacturing and financial laundering, where illegal profits are being routed through complex business structures. Authorities have indicated that once the ED completes its preliminary review, formal money laundering charges may be added, which could significantly widen the scope of the investigation.
The development is being seen as a major escalation in the probe, with agencies now focusing not only on illegal drug manufacturing but also on the financial ecosystem supporting the alleged syndicate.
Officials have confirmed that detailed reports are currently being prepared and will be submitted to the ED shortly, following which further investigative action is expected.
